|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer.
|
31827192 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
|
31820329 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To analyze outcomes of non-small cell lung cancer (NSCLC) patients with brain metastases harboring EGFR or ALK mutations and examine for differences between tyrosine kinase inhibitors (TKIs) alone, radiotherapy (RT) alone (either whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)), or combined TKIs and RT.
|
31812932 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
At the final PFS analysis, alectinib continued to demonstrate superiority in IRF-assessed PFS versus crizotinib in ALK-inhibitor-naïve ALK-positive NSCLC, with a favorable safety profile.OS follow-up continues.
|
31812890 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also discuss practical treatment strategies and possible strategies to overcome or delay resistance to ALK inhibitors.<b>Expert opinion</b>: With a robust treatment armamentarium for patients with <i>ALK</i>-positive NSCLC, emphasis has shifted to optimizing individualized treatment strategies to further enhance outcomes for these patients.
|
31809604 |
2019 |
|
Inflammatory Myofibroblastic Tumor
|
0.700 |
Biomarker
|
disease |
BEFREE |
This report describes a woman aged 22 years with unresectable ALK-negative IMT.
|
31805529 |
2019 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Instead, phosphoproteomics and confirmatory functional studies revealed that the STAT1 overactivation is the key mechanism of ALK-TKI addiction in ALCL.
|
31804622 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.
|
31804622 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.
|
31804622 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
|
31804622 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.
|
31804622 |
2020 |
|
Drug Dependence
|
0.020 |
Biomarker
|
group |
BEFREE |
In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.
|
31804622 |
2020 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Instead, phosphoproteomics and confirmatory functional studies revealed that the STAT1 overactivation is the key mechanism of ALK-TKI addiction in ALCL.
|
31804622 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors.
|
31804301 |
2020 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The patient had a complete response of choroidal metastasis after therapy with ALK tyrosine kinase inhibitors.
|
31804301 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
For non-small cell lung cancer (NSCLC), numerous clinical trials have demonstrated intracranial activity for inhibitors of EGFR and ALK.
|
31803366 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The activation of EGFR-HER2 contributes to the acquisition of resistance to pemetrexed in EML4-ALK rearranged non-small cell lung cancer.
|
31795298 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement identifies a subgroup of patients who are sensitive to ALK tyrosine kinase inhibitors (TKIs).
|
31794921 |
2020 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we described a rare case of ALK-rearranged SCLC responding to ALK inhibitors.
|
31794921 |
2020 |
|
Lymphoepithelial carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In total, there were four EGFR/ALK mutant PLELC patients who received targeted therapy as palliative treatment at the GLCI and in the literature.
|
31794146 |
2020 |
|
Malignant Mesothelioma of Peritoneum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Young patients with peritoneal mesothelioma should be evaluated for the presence of ALK translocations.
|
31783178 |
2020 |
|
Mesothelioma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Presence of an ALK translocation by FISH was seen in 2 of the 32 (6%) mesothelioma patients.
|
31783178 |
2020 |
|
Peritoneal Mesothelioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Young patients with peritoneal mesothelioma should be evaluated for the presence of ALK translocations.
|
31783178 |
2020 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status.
|
31780656 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling.
|
31780656 |
2019 |